Author [ Title(Desc)] Type Year
Filters: Author is Kerkvliet, Nancy I  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Ehrlich AK, Pennington J, Tilton SC, Wang X, Marshall NB, Rohlman D, et al.. AhR activation increases IL-2 production by alloreactive CD4 T cells initiating the differentiation of mucosal-homing Tim3 Lag3 Tr1 cells. Eur J Immunol. 2017 ;47(11):1989-2001.
O'Donnell EF, Saili KS, Koch DC, Kopparapu PR, Farrer D, Bisson WH, et al.. The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS One. 2010 ;5(10).
Cardenas A, Smit E, E Houseman A, Kerkvliet NI, Bethel JW, Kile ML. Arsenic exposure and prevalence of the varicella zoster virus in the United States: NHANES (2003-2004 and 2009-2010). Environ Health Perspect. 2015 ;123(6):590-6.
I
Yu Z, Löhr CV, Fischer KA, Louderback MA, Krueger SK, Dashwood RH, et al.. In utero exposure of mice to dibenzo[a,l]pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor. Cancer Res. 2006 ;66(2):755-62.
O'Connell SG, Kerkvliet NI, Carozza S, Rohlman D, Pennington J, Anderson KA. In vivo contaminant partitioning to silicone implants: Implications for use in biomonitoring and body burden. Environ Int. 2015 ;85:182-8.
M
Bisson WH, Koch DC, O'Donnell EF, Khalil SM, Kerkvliet NI, Tanguay RL, et al.. Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands. J Med Chem. 2009 ;52(18):5635-41.
S
Perkins A, Phillips JL, Kerkvliet NI, Tanguay RL, Perdew GH, Kolluri SK, et al.. A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain. Biology (Basel). 2014 ;3(4):645-69.